Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

BACKGROUND: Patients with inflammatory bowel disease (IBD) receiving anti-TNF and JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed to determine how IBD treatments affect neutralising antibody responses against the Omicron BA.4/5 variant. METHODS: In this multicentre...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhigang, Alexander, James L., Le, Kaixing, Zhou, Xin, Ibraheim, Hajir, Anandabaskaran, Sulak, Saifuddin, Aamir, Lin, Kathy Weitung, McFarlane, Leon R., Constable, Laura, Seoane, Rocio Castro, Anand, Nikhil, Bewshea, Claire, Nice, Rachel, D'Mello, Andrea, Jones, Gareth R., Balarajah, Sharmili, Fiorentino, Francesca, Sebastian, Shaji, Irving, Peter M., Hicks, Lucy C., Williams, Horace RT., Kent, Alexandra J., Linger, Rachel, Parkes, Miles, Kok, Klaartje, Patel, Kamal V., Teare, Julian P., Altmann, Daniel M., Boyton, Rosemary J., Hart, Ailsa L., Lees, Charlie W., Goodhand, James R., Kennedy, Nicholas A., Pollock, Katrina M., Ahmad, Tariq, Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570718/
https://www.ncbi.nlm.nih.gov/pubmed/37842172
http://dx.doi.org/10.1016/j.eclinm.2023.102249

Ejemplares similares

Ejemplares similares